Evidence map›Paper›PMID 42175412›Full record

ArticleMedicine2026

Unveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis.

Wenzhi Du, Dazheng Li, Na Li, Wenxiu Zhang, Jianning Wang, Tianyi Wang, Yong Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenzhi DuBeijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Dazheng LiDepartment of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China.
Na LiMass Spectrometry Research Institute, Beijing Gobroad Healthcare Group, Beijing, China.
Wenxiu ZhangDepartment of Pediatrics, Maternal and Child Health Care Hospital of Shandong Province, Jinan, Shandong Province, China.
Jianning WangDepartment of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China.
Tianyi WangBeijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yong ZengBeijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-6983-0799

Funding

the Natural Science Foundation of Shandong Province Youth Project ZR2024QH279
6 · The paper itself

Abstract

Atherosclerosis is a leading cause of cardiovascular diseases, necessitating the identification of novel therapeutic targets. By utilizing Mendelian randomization, the aim is to identify potential drug targets for the treatment of atherosclerosis. Using results from genomewide association studies and protein quantitative trait loci data, we genetically identified causal effects of levels of several circulating proteins on atherosclerosis risk, validated using multiple statistical approaches, and identified promising drug targets. These findings demonstrated promising targets worthy of further clinical study, especially lipoprotein (a) and proprotein convertase subtilisin/kexin type 9.

Indexed as

AtherosclerosisMendelian Randomization AnalysisGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLipoprotein(a)Proprotein Convertase 9Quantitative Trait LociLipoprotein(a)PCSK9 protein, humanProprotein Convertase 9atherosclerosisdrug targetsmendelian randomization

Identifiers

PMID42175412
PMCPMC13201041

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.